Savara (NASDAQ:SVRA – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.
Valuation and Earnings
This table compares Savara and Aclaris Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Savara | N/A | N/A | -$95.88 million | ($0.53) | -12.21 |
| Aclaris Therapeutics | $18.72 million | 17.77 | -$132.07 million | ($1.38) | -2.22 |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Savara and Aclaris Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Savara | 1 | 1 | 7 | 1 | 2.80 |
| Aclaris Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Savara currently has a consensus price target of $8.57, suggesting a potential upside of 32.48%. Aclaris Therapeutics has a consensus price target of $9.75, suggesting a potential upside of 217.59%. Given Aclaris Therapeutics’ higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Savara.
Profitability
This table compares Savara and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Savara | N/A | -86.60% | -65.44% |
| Aclaris Therapeutics | -900.01% | -39.73% | -27.98% |
Insider and Institutional Ownership
87.9% of Savara shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 5.1% of Savara shares are owned by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Savara has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
Summary
Aclaris Therapeutics beats Savara on 8 of the 14 factors compared between the two stocks.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
